Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
Adaptive Biotechnologies (Nasdaq: ADPT), a commercial stage biotechnology company focused on translating adaptive immune system genetics into clinical products for disease diagnosis and treatment, has announced its third quarter 2024 financial results release date. The company will report its financial results on Thursday, November 7, 2024, after the market closes.
Following the release, Adaptive Biotechnologies will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live audio webcast through the 'Investors' section of the company's website at www.adaptivebiotech.com. For those unable to attend live, an archived version of the webcast will be made available within 24 hours after the event.
Adaptive Biotechnologies (Nasdaq: ADPT), un'azienda di biotecnologie in fase commerciale focalizzata sulla traduzione della genetica del sistema immunitario adattivo in prodotti clinici per la diagnosi e il trattamento delle malattie, ha annunciato la data di rilascio dei risultati finanziari del terzo trimestre 2024. L'azienda presenterà i suoi risultati finanziari giovedì 7 novembre 2024, dopo la chiusura del mercato.
Dopo il rilascio, Adaptive Biotechnologies ospiterà una conference call e una trasmissione in diretta alle 13:30 ora della Costa Pacifica / 16:30 ora della Costa Orientale nello stesso giorno. Gli investitori possono accedere alla trasmissione audio in diretta tramite la sezione 'Investitori' del sito web dell'azienda all'indirizzo www.adaptivebiotech.com. Per coloro che non possono partecipare in diretta, una versione archiviata della trasmissione sarà disponibile entro 24 ore dopo l'evento.
Adaptive Biotechnologies (Nasdaq: ADPT), una empresa de biotecnología en etapa comercial centrada en traducir la genética del sistema inmunológico adaptativo en productos clínicos para el diagnóstico y tratamiento de enfermedades, ha anunciado la fecha de publicación de sus resultados financieros del tercer trimestre de 2024. La compañía informará sus resultados financieros el jueves 7 de noviembre de 2024, después del cierre del mercado.
Posteriormente, Adaptive Biotechnologies realizará una llamada de conferencia y transmisión web a la 1:30 p.m. hora del Pacífico / 4:30 p.m. hora del Este el mismo día. Los inversores pueden acceder a la transmisión de audio en vivo a través de la sección 'Inversores' del sitio web de la compañía en www.adaptivebiotech.com. Para aquellos que no puedan asistir en vivo, se hará disponible una versión archivada de la transmisión dentro de las 24 horas posteriores al evento.
Adaptive Biotechnologies (Nasdaq: ADPT)는 질병 진단 및 치료를 위한 임상 제품으로 적응 면역 체계 유전학을 전환하는 것에 주력하는 상업 단계의 생명공학 회사로, 2024년 3분기 재무 결과 발표 날짜를 발표했습니다. 회사는 2024년 11월 7일 목요일에 시장 마감 후 재무 결과를 보고할 예정입니다.
발표 후, Adaptive Biotechnologies는 같은 날 오후 1시 30분(태평양 표준시) / 오후 4시 30분(동부 표준시)에 컨퍼런스 콜 및 웹캐스트를 주최합니다. 투자자들은 www.adaptivebiotech.com의 '투자자' 섹션을 통해 실시간 오디오 웹캐스트에 접근할 수 있습니다. 실시간 참석이 불가능한 분들을 위해, 이벤트 후 24시간 이내에 기록된 버전의 웹캐스트가 제공될 것입니다.
Adaptive Biotechnologies (Nasdaq: ADPT), une entreprise de biotechnologie en phase commerciale axée sur la traduction de la génétique du système immunitaire adaptatif en produits cliniques pour le diagnostic et le traitement des maladies, a annoncé la date de publication de ses résultats financiers pour le troisième trimestre 2024. L'entreprise présentera ses résultats financiers le jeudi 7 novembre 2024, après la clôture des marchés.
À la suite de cette publication, Adaptive Biotechnologies organisera une conférence téléphonique et un webinaire à 13h30, heure du Pacifique / 16h30, heure de l'Est le même jour. Les investisseurs peuvent accéder au webinaire audio en direct via la section 'Investisseurs' du site Web de la société à l'adresse www.adaptivebiotech.com. Pour ceux qui ne peuvent pas assister en direct, une version archivée du webinaire sera disponible dans les 24 heures suivant l'événement.
Adaptive Biotechnologies (Nasdaq: ADPT), ein biotechnologisches Unternehmen in der Handelsphase, das sich darauf konzentriert, die Genetik des adaptiven Immunsystems in klinische Produkte für die Diagnose und Behandlung von Krankheiten zu übersetzen, hat den Termin zur Veröffentlichung der finanziellen Ergebnisse für das dritte Quartal 2024 bekannt gegeben. Das Unternehmen wird seine finanziellen Ergebnisse am Donnerstag, den 7. November 2024, nach Börsenschluss bekannt geben.
Nach der Veröffentlichung wird Adaptive Biotechnologies am selben Tag um 13:30 Uhr pazifischer Zeit / 16:30 Uhr östlicher Zeit eine Telefonkonferenz und einen Webcast veranstalten. Investoren können über den Bereich 'Investoren' der Unternehmenswebsite www.adaptivebiotech.com auf den Live-Audio-Webcast zugreifen. Für diejenigen, die nicht live teilnehmen können, wird innerhalb von 24 Stunden nach der Veranstaltung eine archivierte Version des Webcasts zur Verfügung stehen.
- None.
- None.
SEATTLE, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2024 after market close on Thursday, November 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com
FAQ
When will Adaptive Biotechnologies (ADPT) report its Q3 2024 financial results?
What time is the Adaptive Biotechnologies (ADPT) Q3 2024 earnings call scheduled for?
Where can I access the webcast for Adaptive Biotechnologies' (ADPT) Q3 2024 earnings call?
Will Adaptive Biotechnologies (ADPT) provide a replay of their Q3 2024 earnings call?
